837390-55-3

Basic information

• Product Name: 4-benzyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid
• Synonyms: 4-benzyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid
• CAS NO: 837390-55-3
• Molecular Formula: C₁₄H₁₁NO₂S
• Molecular Weight: 257.30764
• Mol File: 837390-55-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-benzyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-benzyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid(837390-55-3)
• EPA Substance Registry System: 4-benzyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid(837390-55-3)

Safety Data

• Hazardous Substances Data: 837390-55-3(Hazardous Substances Data)

Upstream product

• 1056976-66-9 ethyl (Z)-2-azido-3-(2-thienyl)prop-2-enoate 
• 98-03-3 thiophene-2-carbaldehyde 
• 100-39-0 benzyl bromide 
• 606102-24-3 ethyl 4-benzyl-4H-thieno[3,2-b]pyrrole-5-carboxylate 
• 46193-76-4 ethyl 4H-thieno[3,2-b]pyrrole-5-carboxylate 

Relevant articles and documents

New 4H-thieno[3,2-b]pyrrole-5-carboxamides

[Figure not available: see fulltext.] A series of N-substituted 4H-thieno[3,2-b]pyrrole-5-carboxylic acids and their imidazolyl derivatives was synthesized. 4-Methyl-, 4-allyl-, and 4-benzyl derivatives of (4H-thieno[3,2-b]pyrrol-5-yl)carboxylic acid or their imidazolides were used in reactions with EtNH2 and indole sodium salt, providing the respective amides.

New sulfanilamide derivatives incorporating heterocyclic carboxamide moieties as carbonic anhydrase inhibitors

Carbonic Anhydrases (CAs) are ubiquitous metalloenzymes involved in several disease conditions. There are 15 human CA (hCA) isoforms and their high homology represents a challenge for the discovery of potential drugs devoid of off-target side effects. For this reason, many synthetic and pharmacologic research efforts are underway to achieve the full pharmacological potential of CA modulators of activity. We report here a novel series of sulfanilamide derivatives containing heterocyclic carboxamide moieties which were evaluated as CA inhibitors against the physiological relevant isoforms hCA I, II, IX, and XII. Some of them showed selectivity toward isoform hCA II and hCA XII. Molecular docking was performed for some of these compounds on isoforms hCA II and XII to understand the possible interaction with the active site amino acid residues, which rationalized the reported inhibitory activity.

Thienopyrrole amide derivative and application of thienopyrrole amide derivative in antitumor drugs

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a thienopyrrole amide derivative and a preparation method thereof, and application of the thienopyrrole amide derivative as an MEK inhibitor in antitumor drugs. The invention provides a thienopyrrole amide derivative as shown in a general formula, and a geometric isomer or pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof. The MEK inhibitor has specificity and effectiveness, and has a wider development prospect. Experimental results show that the thienopyrrole amide derivative synthesized by the research group has a prospect of developing targeted antitumor drugs.

Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration

Lysine specific demethylase 1 KDM1A (LSD1) regulates histone methylation and it is increasingly recognized as a potential therapeutic target in oncology. We report on a high-throughput screening campaign performed on KDM1A/CoREST, using a time-resolved fluorescence resonance energy transfer (TR-FRET) technology, to identify reversible inhibitors. The screening led to 115 hits for which we determined biochemical IC50, thus identifying four chemical series. After data analysis, we have prioritized the chemical series of N-phenyl-4H-thieno[3, 2-b]pyrrole-5-carboxamide for which we obtained X-ray structures of the most potent hit (compound 19, IC50 = 2.9 μM) in complex with the enzyme. Initial expansion of this chemical class, both modifying core structure and decorating benzamide moiety, was directed toward the definition of the moieties responsible for the interaction with the enzyme. Preliminary optimization led to compound 90, which inhibited the enzyme with a submicromolar IC50 (0.162 μM), capable of inhibiting the target in cells.

MODULATORS OF LIPID STORAGE

Disclosed are compounds of formulas I, II, and III: Formulas I, II, and III wherein R1-R19 and n are as described herein, or pharmaceutically acceptable salts thereof, or an enantiomer thereof or a conjugate thereof wherein the conju